KR100533618B1 - 당뇨병 치료를 위한 방법 및 조성물 - Google Patents

당뇨병 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR100533618B1
KR100533618B1 KR10-2000-7001386A KR20007001386A KR100533618B1 KR 100533618 B1 KR100533618 B1 KR 100533618B1 KR 20007001386 A KR20007001386 A KR 20007001386A KR 100533618 B1 KR100533618 B1 KR 100533618B1
Authority
KR
South Korea
Prior art keywords
delete delete
zinc
hispro
composition
arachidonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-2000-7001386A
Other languages
English (en)
Korean (ko)
Other versions
KR20010022786A (ko
Inventor
문케이. 송
Original Assignee
문케이. 송
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 문케이. 송 filed Critical 문케이. 송
Publication of KR20010022786A publication Critical patent/KR20010022786A/ko
Application granted granted Critical
Publication of KR100533618B1 publication Critical patent/KR100533618B1/ko
Assigned to 주식회사 싸이클로지 reassignment 주식회사 싸이클로지 권리의 전부이전등록 Assignors: 송,문케이.
Assigned to 주식회사 노브메타파마 reassignment 주식회사 노브메타파마 권리의 전부이전등록 Assignors: 주식회사 싸이클로지
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR10-2000-7001386A 1997-08-11 1998-08-06 당뇨병 치료를 위한 방법 및 조성물 Expired - Lifetime KR100533618B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/909,240 US5834032A (en) 1997-08-11 1997-08-11 Compositions and methods for treating diabetes
US08/909,240 1997-08-11
PCT/US1998/016321 WO1999007224A1 (en) 1997-08-11 1998-08-06 Compositions and methods for treating diabetes

Publications (2)

Publication Number Publication Date
KR20010022786A KR20010022786A (ko) 2001-03-26
KR100533618B1 true KR100533618B1 (ko) 2005-12-06

Family

ID=25426873

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-7001386A Expired - Lifetime KR100533618B1 (ko) 1997-08-11 1998-08-06 당뇨병 치료를 위한 방법 및 조성물

Country Status (6)

Country Link
US (1) US5834032A (https=)
JP (1) JP2001513487A (https=)
KR (1) KR100533618B1 (https=)
CN (1) CN1216635C (https=)
AU (1) AU8693098A (https=)
WO (1) WO1999007224A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
EP1115389B1 (en) * 1998-09-25 2014-03-12 PhilERA New Zealand Limited Fructosamine oxidase: antagonists and inhibitors
JP2001220348A (ja) * 1999-11-30 2001-08-14 Japan Science & Technology Corp 亜鉛（ｉｉ）有機錯体からなる血糖降下剤
WO2002011676A2 (en) 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
JP4161031B2 (ja) * 2000-10-31 2008-10-08 独立行政法人産業技術総合研究所 亜鉛含有リン酸カルシウム微粒子含有懸濁液または粒子溶媒混合系及び亜鉛欠乏症治療剤
JP2003040784A (ja) * 2001-01-31 2003-02-13 Japan Science & Technology Corp 血糖降下剤
NZ539735A (en) * 2002-10-02 2009-07-31 Dmi Biosciences Inc Diagnosis and monitoring of diseases using markers, such as diketopiperazines
US6989025B2 (en) * 2002-10-04 2006-01-24 Boston Scientific Scimed, Inc. Extruded tubing with discontinuous striping
WO2004064742A2 (en) * 2003-01-17 2004-08-05 Uab Research Foundation Methods and compositions for p2x receptor calcium entry channels and other calcium entry mechanisms
EP1442741B1 (en) * 2003-01-31 2008-01-16 United States Government as represented by the Department of Veterans Affaires, At the Office of General Counsel - PSG IV (024) Compositions and methods for treating obesity
EP1622633B1 (en) 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
JP2008538547A (ja) * 2005-03-09 2008-10-30 ロジャー・ウィリアムズ・ホスピタル 甲状腺刺激ホルモン放出ホルモン類縁体及び使用方法
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
KR101530050B1 (ko) * 2007-03-02 2015-06-22 주식회사 노브메타파마 알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
CN103841974A (zh) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
US20170143701A1 (en) * 2014-06-20 2017-05-25 Suntory Holdings Limited Carbohydrate metabolism-ameliorating agent
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN105748564A (zh) * 2015-12-21 2016-07-13 天津中津药业股份有限公司 一种治疗糖尿病的药物组合物
EP3698801B1 (en) * 2017-10-20 2024-09-04 Novmetapharma Co., Ltd. Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients
JP6944221B2 (ja) * 2017-11-20 2021-10-06 ノブメタファーマ カンパニー リミテッド Ｃｈｐ（シクロ−ヒスプロ）を含む骨損失疾患の予防、改善または治療用組成物
US20210177932A1 (en) * 2017-12-11 2021-06-17 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for prevention and treatment of immune deficiency and inflammation
KR20190074746A (ko) * 2017-12-20 2019-06-28 주식회사 노브메타파마 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
US20200345728A1 (en) * 2019-04-30 2020-11-05 Novmetapharma Co., Ltd. Compositions and methods for treatment of atherosclerosis
KR102115353B1 (ko) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
CA3162366C (en) * 2019-12-20 2023-03-14 Peter Novak Composition and method for the treatment of type i diabetes
KR20230025709A (ko) * 2020-06-17 2023-02-22 주식회사 노브메타파마 바이러스 감염을 치료하기 위한 조성물 및 방법
CN115884769A (zh) 2020-09-04 2023-03-31 雀巢产品有限公司 用于向动物提供健康益处的组合物和方法
KR20240032221A (ko) * 2022-08-31 2024-03-12 주식회사 노브메타파마 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 호흡기 질환의 예방, 개선 또는 치료용 조성물
KR20250066976A (ko) 2023-11-07 2025-05-14 주식회사 노브메타파마 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 당뇨병성 신증의 예방, 개선 또는 치료용 조성물
JP2025084032A (ja) 2023-11-21 2025-06-02 ノブメタファーマ カンパニー リミテッド グルコン酸亜鉛塩およびシクロ－ヒスプロを有効成分として含む肥満および糖尿病の予防、改善または治療用組成物

Also Published As

Publication number Publication date
HK1031174A1 (en) 2001-06-08
US5834032A (en) 1998-11-10
CN1216635C (zh) 2005-08-31
WO1999007224A1 (en) 1999-02-18
KR20010022786A (ko) 2001-03-26
AU8693098A (en) 1999-03-01
JP2001513487A (ja) 2001-09-04
CN1265560A (zh) 2000-09-06

Similar Documents

Publication Publication Date Title
KR100533618B1 (ko) 당뇨병 치료를 위한 방법 및 조성물
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
US5780489A (en) Method for treating amyotrophic lateral sclerosis
US9050306B2 (en) Activation of AMP-protein activated kinase by oxaloacetate compounds
JPH07206676A (ja) 糖尿病の治療用薬剤
CN107441104A (zh) 人参二醇皂苷Rb组分防治糖尿病并发症及代谢紊乱相关疾病的医药用途
WO2023023397A1 (en) Methods for inhibiting the progression of neurodegenerative diseases
EP3081097B1 (en) Composition for the treatment of infertility
US20110064773A1 (en) pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
US20110028554A1 (en) pharmaceutical compositions comprising diiodothyronine and their therapeutic use
Udaipurwala et al. Exploring the Pharmacotherapeutic Potential of Natural Compound Alpha Lipoic Acid
US20220331341A1 (en) Treatment comprising the use of fxr agonists
EP2517701B1 (en) Vicinal dithioglycol for use in preventing pathological processes induced by alcohol consumption
AU2003213027A1 (en) Therapeutic and prophylactic treatment of aging and disorders of aging in humans
CN101115483A (zh) 含有FBPase抑制剂的药物组合物
US11510889B2 (en) Methods for inhibiting the progression of neurodegenerative diseases
KR102478582B1 (ko) 에버닉산을 유효성분으로 함유하는 파킨슨 질환 예방 또는 치료용 조성물
Mechirova et al. Randomized, double blind, placebo controlled trial of hydrosoluble ubiquinol and carnitine in patients with heart failure: longterm follow up results in the Tishcon study
JP2008508312A (ja) 筋肉エネルギー産生増強目的のためのメチルピルベートの用途
CN120475966A (zh) D10-二十二碳六烯酸或其酯的药物组合物
Srivastava et al. PHYTOPHARMACOLGICAL EVALUATION OF POLYHERBAL PREPARATION FOR HYPOGLYCEMIC ACTIVITY IN DIABETIC RATS
CN111228263A (zh) 乙基甲基羟基吡啶苹果酸盐或其药物组合物，预防和/或治疗ⅱ型糖尿病的用途
HK1031174B (en) Compositions and methods for treating diabetes
WO2007014248A2 (en) Method of reducing food intake

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20000210

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030710

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050630

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20051011

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20051129

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20051130

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20081126

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20091123

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20101126

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20111122

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20121120

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20121120

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20131118

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20131118

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20141124

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20141124

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20151124

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20151124

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20161114

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20161114

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20171017

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20171017

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20190206

Termination category: Expiration of duration